Press Release Archive
Press Releases
June 2023
06.01.2023 Research and Pipeline Research Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
May 2023
05.31.2023 Vaccines Vaccines U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults 05.30.2023 Research and Pipeline Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial 05.25.2023 Research and Pipeline Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting 05.25.2023 Prescription Medicines Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 05.18.2023 Research and Pipeline Vaccines FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization 05.16.2023 Corporate Financial Pfizer Prices $31,000,000,000 Debt Offering 05.15.2023 Pfizer Announces Proposed Notes Offering 05.09.2023 Partnerships Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets 05.08.2023 Corporate Partnerships Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 05.02.2023 Finance Pfizer Reports First-Quarter 2023 Results
April 2023
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.